lamivudine + abacavir + amprenavir + indinavir

A four-drug combination of **lamivudine**, **abacavir**, **amprenavir**, and **indinavir**, each of which is an antiretroviral used in the treatment of HIV infection. - **Lamivudine** and **abacavir** are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit the activity of HIV reverse transcriptase, thereby preventing viral replication[1][5]. - **Amprenavir** and **indinavir** are protease inhibitors, which block the HIV protease enzyme necessary for the maturation of infectious viral particles. - This combination targets two steps in the HIV lifecycle (reverse transcription and protease-mediated maturation), intended to reduce viral load and delay resistance. - No single fixed-dose, co-formulated branded product containing this exact four-drug combination is marketed. - Studied in clinical trials as a regimen for HIV-1 infection, but not widely used or marketed as a fixed combination tablet.